What’s On CEO Andrew Witty’s To-Do List Before Exiting GSK
Executive Summary
The company showed signs of stabilization in the first quarter, as Witty insisted his diversified strategy is beginning to pay off. But a new CEO will have to contend with the potential entry of Advair generics.
You may also be interested in...
Stayin’ Alive: GSK Sees Options For Brand Advair In A Post-Generic World
Payers might be open to keeping the Advair brand on formulary even if a generic becomes available, because GSK has a portfolio of respiratory drugs to leverage in negotiations, CEO Andrew Witty said during the company’s third quarter conference call.
Stayin’ Alive: GSK Sees Options For Brand Advair In A Post-Generic World
Payers might be open to keeping the Advair brand on formulary even if a generic becomes available, because GSK has a portfolio of respiratory drugs to leverage in negotiations, CEO Andrew Witty said during the company’s third quarter conference call.
Teva Advancing Two Advair Generics With Late 2017 Target
Teva will move forward an internal generic Advair candidate and one acquired from Allergan to improve its chances of getting an interchangeable version of the market-leading asthma drug approved by FDA.